Our Company
Presentation
Management Team
Board of directors
Scientific Advisory Board
Contact
Products
Tedopi®
OSE-279
Lusvertikimab (OSE-127)
Pegrizeprument (FR104)
BI 770371
ABBV-230
CLEC-1
Research & Development
Scientific publications
Investors
Press Releases
Regulated information
Financial documents
General Shareholders’ meetings
Partnerships
Pharma partnerships
Clinical partnerships
Academic and public Partnerships
News
Agenda
Press Releases
Contact
en
fr
P
r
o
j
e
c
t
s
A
r
c
h
i
v
e
s
October 2021
First-half 2020 financial report
October 2021
2019 Universal registration document
October 2021
First-half 2019 financial report (in French)
Précédent
1
2